Clinical Trial Update: Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Fruquintinib as second-line treatment for advanced/metastatic biliary tract adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Adenocarcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Sichuan University | Conditions: Biliary Tract Adenocarcinoma | Phase 2 | Status: UNKNOWN